J&J raises FY26 outlook following positive Q2 - Pharmaceutical Technology

Contributing around $8.9bn to its Q2 revenues of around $25.3bn, J&J MedTech’s performance was driven by its cardiovascular portfolio that includes the Shockwave IVL system. Contributing around $8.9bn to its Q2 revenues of around $25.3bn, J&J MedTech’s performance was driven by its cardiovascular portfolio that includes the Shockwave IVL system. While J&J MedTech reported strong performance, it missed analysts’ expectations by around $400m, as per data compiled by the London Stock Exchange Group (LSEG). Credit: josefkubes/Shutterstock.com Johnson and Johnson (J&J) has achieved Q2 revenues totalling around $25.3bn, representing a year-over-year (YoY) uptick of 6.6%, with the company’s medtech division, J&J…

Source: Pharmaceutical Technology